The full docs? They've announced the purpose of the CR already. All that's left is the appendix 3b I would have thought.
Happy to be proven wrong.
Regardless, we'll need to see what % of the 1c shares Patos ends up taking because as we've seen previously, the overhang from Patos last time was debilitating to the share price. Brokers are rarely around for the long game. Combined with their placement fee (say, 5% of funds raised, maybe $500k or so) they can flip their 1c shares for a pip or two and still be making-out like bandits. Even if they take 500M of the 1B shares and flipped them for 1 pip, they'd be making another $500k, in addition to their placement fee.
That's a super cool $1M for finding a bunch of s.708 investors willing to take-on shares at 56% below the last traded price.
We will need a truly big event to clear-out the 500M or more overhang but hey - PYC traded ~350M shares back in April after that announcement, so who knows...
- Forums
- ASX - By Stock
- Ann: Entitlement Issue
PYC
pyc therapeutics limited
Add to My Watchlist
0.40%
!
$1.27

The full docs? They've announced the purpose of the CR already....
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M |
Open | High | Low | Value | Volume |
$1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 1380 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | 1.265 |
1 | 15000 | 1.260 |
1 | 12000 | 1.255 |
1 | 4000 | 1.225 |
1 | 20000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.290 | 25630 | 2 |
1.295 | 24500 | 1 |
1.300 | 59168 | 4 |
1.325 | 9001 | 1 |
1.330 | 20000 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online